Medicus Pharma Proposes $135 Million SkinJect SPAC Combination

Medicus Pharma announced Wednesday that its proposed SPAC transaction for SkinJect contemplates a $135 million pre-money enterprise valuation, with financing details and final ownership unresolved. The nonbinding letter of intent was signed Wednesday, Nov. 4, by Skinject, Inc. (SkinJect), Medicus’ wholly owned subsidiary, and a special purpose acquisition company whose identity has not been disclosed. The proposal also contemplates a concurrent equity financing. The $135 million figure is SkinJect’s proposed valuation before that financing, not the amount being raised; the financing’s size and terms have not been disclosed.

Source: TokenPost